<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>BiG生物创新社 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-23T12:02:12+08:00</updated>
  <subtitle>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>盘点｜肿瘤干细胞药物开发的四条通路及主要靶点！</title>
    <updated>2021-01-22T15:48:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/e_cvInoUSPsnN14ZDnskvw</id>
    <link href="https://mp.weixin.qq.com/s/e_cvInoUSPsnN14ZDnskvw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新江湖｜徐琦、刘佳凝、朱枫、郎帼娜、张妍加入BiG！</title>
    <updated>2021-01-22T15:48:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/409dsez7olZOYA6cYjrWxQ</id>
    <link href="https://mp.weixin.qq.com/s/409dsez7olZOYA6cYjrWxQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>又一重磅Deal, 科望医药1.17亿美元引入VEGF/DLL4双抗！</title>
    <updated>2021-01-21T13:00:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/8oFUIgWiSOFLQfIT4OQ-Jg</id>
    <link href="https://mp.weixin.qq.com/s/8oFUIgWiSOFLQfIT4OQ-Jg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>五位大咖谈IO｜单抗/ADC赛道，新靶点如何困境突围？</title>
    <updated>2021-01-19T17:00:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/g1qSsbCfB4nXK9KEUGdRMA</id>
    <link href="https://mp.weixin.qq.com/s/g1qSsbCfB4nXK9KEUGdRMA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新江湖｜自贸壹号加入BiG会员机构！</title>
    <updated>2021-01-19T17:00:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/nT6b1qb23k0zea_VOA6jBg</id>
    <link href="https://mp.weixin.qq.com/s/nT6b1qb23k0zea_VOA6jBg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康PD-1/CTLA-4双抗，增强对PD-1+活化T细胞CTLA-4的阻断作用</title>
    <updated>2021-01-15T17:00:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/BogmE5ys86BAHGRJspYqyg</id>
    <link href="https://mp.weixin.qq.com/s/BogmE5ys86BAHGRJspYqyg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>五位大咖谈CAR-T｜成本及定价，降VS不降，谁说了算？</title>
    <updated>2021-01-14T07:52:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/GHuZBr3dwkN7nW3HAw6a7g</id>
    <link href="https://mp.weixin.qq.com/s/GHuZBr3dwkN7nW3HAw6a7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>邀 | Biofuture 2021 下一代抗体药技术创新大会 &amp; 细胞与基因治疗创新大会</title>
    <updated>2021-01-14T07:52:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/4eQX39EgvSm1umnXuCrBoA</id>
    <link href="https://mp.weixin.qq.com/s/4eQX39EgvSm1umnXuCrBoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>盘点！靶向细胞凋亡的药物开发</title>
    <updated>2021-01-12T17:13:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/34NGlF38QEReOzRRljj_Sw</id>
    <link href="https://mp.weixin.qq.com/s/34NGlF38QEReOzRRljj_Sw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新江湖｜娄实、戴晗、杨修诰、崔平、黄浩旻加入BiG！</title>
    <updated>2021-01-12T17:13:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/ZEtBDFGdmiqeCVld_jGqhQ</id>
    <link href="https://mp.weixin.qq.com/s/ZEtBDFGdmiqeCVld_jGqhQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新江湖｜阿诺医药加入BiG会员机构！</title>
    <updated>2021-01-12T17:13:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/lEwTzKT-9aGD66EyS6bBmw</id>
    <link href="https://mp.weixin.qq.com/s/lEwTzKT-9aGD66EyS6bBmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>千人在线！科学家创业会是中国FIC新药的答案么？</title>
    <updated>2021-01-09T22:22:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-09:/s/U0D3WN-AmwhF4tEaWlfD1A</id>
    <link href="https://mp.weixin.qq.com/s/U0D3WN-AmwhF4tEaWlfD1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>邀丨会前通知，BIO APAC多的是你不知道的事！</title>
    <updated>2021-01-09T22:22:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-09:/s/lopL_-Xa6OGuEXfKhBBrJg</id>
    <link href="https://mp.weixin.qq.com/s/lopL_-Xa6OGuEXfKhBBrJg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>李金泽｜生物学驱动的CD3双抗一期临床开发</title>
    <updated>2021-01-06T17:37:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/urCX9mIH_ce2lXZtwe2fqw</id>
    <link href="https://mp.weixin.qq.com/s/urCX9mIH_ce2lXZtwe2fqw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>苏桥生物与非同生物就多个抗体创新生物药签署战略合作协议</title>
    <updated>2021-01-06T17:37:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/vWx9j-M1qxJpxAgcdPCpQQ</id>
    <link href="https://mp.weixin.qq.com/s/vWx9j-M1qxJpxAgcdPCpQQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>简述四种NK细胞疗法耐药机制</title>
    <updated>2021-01-06T16:48:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/6nFw2OvUTJhM7ByZPPtl7g</id>
    <link href="https://mp.weixin.qq.com/s/6nFw2OvUTJhM7ByZPPtl7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>周五直播｜科学家创业工作坊，你可能不知道的N个坑</title>
    <updated>2021-01-06T16:48:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/oJ6tHBEqgQGgW2_aJsJVHw</id>
    <link href="https://mp.weixin.qq.com/s/oJ6tHBEqgQGgW2_aJsJVHw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新的策略来定义Tregs！</title>
    <updated>2021-01-04T17:13:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/tybgDJI_AK9PB9ECtfYw_Q</id>
    <link href="https://mp.weixin.qq.com/s/tybgDJI_AK9PB9ECtfYw_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新江湖｜水木未来加入BiG会员机构！</title>
    <updated>2021-01-04T17:13:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/p0X4uhr0Ub8Q-JU8UIdoYQ</id>
    <link href="https://mp.weixin.qq.com/s/p0X4uhr0Ub8Q-JU8UIdoYQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再极医药完成近2亿元人民币C轮融资，优选资本领投！</title>
    <updated>2021-01-04T17:13:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/nKTZCJ4puCizSxUig06IzA</id>
    <link href="https://mp.weixin.qq.com/s/nKTZCJ4puCizSxUig06IzA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>